Biohaven gives important update on phase 2/3 trial and Alzheimer’s disease program
Biohaven Pharmaceutical Holding Company Ltd has announced completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical...
NIH & BARDA react to emergency use authorisation of Moderna Covid-19 vaccine by FDA
NIH and BARDA have reacted to the United States Food and Drug Administration's Emergency Use Authorization (EUA) to Moderna, Inc., a biotechnology company based...
Research on preventative nasal spray reveals interesting results
Research on a 'novel' nasal spray therapy, INNA-051, which has been shown to reduce Covid-19 viral replication by up to 96 percent in a...
BAT moves Covid candidate vaccine towards Phase I human clinical trials
BAT has announced plans to commence a Phase I first-time-in-human study of its Covid-19 vaccine candidate.
The announcement by BAT's US Bio-tech arm, Kentucky BioProcessing...
Sputnik V vaccine’s efficacy confirmed at 91.4%
Sputnik V, the Russian Covid-19 vaccine, has passed a crucial test. Its efficacy has been confirmed at 91.4 per cent bsed on data analysis...
Covid breakthrough: Baricitinib plus remdesivir show promising results in treating Corona infection
Covid treatment is no more a dream. In a relif to those who are waiting for Covid-19 medicine, it has emerged that combination of...
Piramal Pharma Solutions on expansion mode, invests ~$32 Million
Piramal Pharma Solutions, a Piramal Pharma Limited business and a leading Contract Development and Manufacturing Organization (CDMO), has revealed its plans to expand its...
FlowMetric introduces ‘breakthrough’ Covid-19 antibody test
FlowMetric has launched a 'powerful advancement' in Covid-19 antibody testing that the company said delivers exceptional performance compared to existing tests on the global...
Diabeloop launches DBL-hu to manage highly unstable diabetes
Diabeloop said it has received CE marking for its adjustable and innovative technological solution called DBL-hu.
The solution, according Diabeloop, enhances glycemic control and satisfaction...
AstraZeneca starts Phase 2b clinical study of medicine to lower cholesterol: Ionis
Ionis Pharmaceuticals, Inc. has said that the AstraZeneca has commenced a Phase 2b clinical trial of ION449 (AZD8233).
It is an investigational antisense medicine designed...
